In this context, pembrolizumab and nivolumab as anti-PD-1 checkpoint inhibitors have been reported to predict the prognostic significance of TILs in a variety of solid tumors, including NSCLC [24, 25]. Here, PDCD1 is linked to non-small cell lung carcinoma.